» Articles » PMID: 38138292

Gut Microbiota's Oxalate-Degrading Activity and Its Implications on Cardiovascular Health in Patients with Kidney Failure: A Pilot Prospective Study

Overview
Publisher MDPI
Specialty General Medicine
Date 2023 Dec 23
PMID 38138292
Authors
Affiliations
Soon will be listed here.
Abstract

: The present study aims to investigate the association between gut microbiota's oxalate-degrading activity (ODA) and the risk of developing cardiovascular disease (CVD) over a three-year follow-up period in a cohort of patients undergoing kidney replacement therapy (KRT). Additionally, various factors were examined to gain insight into the potential mechanisms underlying the ODA-CVD link. : A cohort of 32 KRT patients and 18 healthy volunteers was enrolled in this prospective observational pilot study. Total fecal ODA, routine clinical data, plasma oxalic acid (POx), serum indoxyl sulfate, lipid profile, oxidative stress, and proinflammatory markers were measured, and the patients were followed up for three years to assess CVD events. : The results revealed that patients with kidney failure exhibited significantly lower total fecal ODA levels compared to the healthy control group ( = 0.017), with a higher proportion showing negative ODA status (≤-1% per 0.01 g) ( = 0.01). Negative total fecal ODA status was associated with a significantly higher risk of CVD events during the three-year follow-up period (HR = 4.1, 95% CI 1.4-16.3, = 0.003), even after adjusting for potential confounders. Negative total fecal ODA status was significantly associated with elevated POx and indoxyl sulfate levels and linked to dyslipidemia, increased oxidative stress, and inflammation, which are critical contributors to CVD. : The findings contribute novel insights into the relationship between gut microbiota's ODA and cardiovascular health in patients undergoing KRT, emphasizing the need for further research to elucidate underlying mechanisms and explore potential therapeutic implications of targeting gut microbiota's ODA in this vulnerable population.

Citing Articles

L. (Oxalidaceae): From Invasive Concern to Promising Bioresource for Health and Sustainable Applications.

Malfa G, Bianchi S, Spadaro V, Di Giacomo C, Raimondo F, Acquaviva R Plants (Basel). 2025; 14(4).

PMID: 40006837 PMC: 11858978. DOI: 10.3390/plants14040578.


Association between serum total indoxyl sulfate, intraperitoneal inflammation, and peritoneal dialysis technique failure: a 3-year prospective cohort study.

Stepanova N, Driianska V, Korol L, Snisar L BMC Nephrol. 2024; 25(1):475.

PMID: 39741261 PMC: 11689590. DOI: 10.1186/s12882-024-03935-x.


Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes.

Stepanova N Biomedicines. 2024; 12(10).

PMID: 39457689 PMC: 11505255. DOI: 10.3390/biomedicines12102377.

References
1.
Khan S . Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol. 2014; 3(3):256-276. PMC: 4220551. DOI: 10.3978/j.issn.2223-4683.2014.06.04. View

2.
Li Q, Zhang S, Wu Q, Xiao J, Wang Z, Mu X . Serum total indoxyl sulfate levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study. BMC Nephrol. 2022; 23(1):231. PMC: 9238151. DOI: 10.1186/s12882-022-02862-z. View

3.
McFarlane C, Krishnasamy R, Stanton T, Savill E, Snelson M, Mihala G . Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial. Nutrients. 2021; 13(12). PMC: 8708915. DOI: 10.3390/nu13124481. View

4.
Kumar P, Saini K, Saini V, Mitchell T . Oxalate Alters Cellular Bioenergetics, Redox Homeostasis, Antibacterial Response, and Immune Response in Macrophages. Front Immunol. 2021; 12:694865. PMC: 8566947. DOI: 10.3389/fimmu.2021.694865. View

5.
Foresto-Neto O, Ghirotto B, Camara N . Renal Sensing of Bacterial Metabolites in the Gut-kidney Axis. Kidney360. 2022; 2(9):1501-1509. PMC: 8786145. DOI: 10.34067/KID.0000292021. View